Australian regulator warns of counterfeit retatrutide after patient suffers torn oesophagus

A severe injury triggers a national warning

Australia’s medicines regulator has issued a new warning about counterfeit products sold as retatrutide after a patient suffered uncontrollable vomiting and a torn oesophagus. The person required hospital treatment after using what they believed was an experimental weight-loss medicine. The Therapeutic Goods Administration examined a sample and found that it contained no retatrutide at all. Instead, it contained semaglutide at approximately eight times the concentration found in approved semaglutide products assessed by the agency.

Retatrutide is an experimental peptide medicine that has not been approved for sale or prescription in Australia. Nevertheless, products bearing that name, along with labels such as Reta, R-10 and R-20, are promoted through social-media channels and other unregulated markets. They may arrive as powders or liquids in unmarked vials, leaving buyers without reliable information about the active ingredient, dose, sterility or manufacturing conditions.

Why the case matters beyond Australia

The episode illustrates a wider regulatory problem created by intense demand for weight-loss treatments. Semaglutide is a real pharmaceutical ingredient used in authorised medicines, but an unexpected and highly concentrated dose can expose a user to serious adverse effects. A product’s use of a familiar drug name therefore offers no assurance that its contents, strength or production standards match an authorised medicine. Injectable counterfeits add risks from contamination, unsafe preparation and dosing mistakes.

Comparable concerns have prompted enforcement elsewhere. Britain’s Medicines and Healthcare products Regulatory Agency published a decision on September 9 requiring a pharmacy business to change advertising that promoted unauthorised or prescription-only weight-loss products to the public. The agency said medicines should not be marketed before regulators have assessed their safety, quality and effectiveness, and that treatment choices should follow consultation with a healthcare professional.

Regulators are targeting both products and promotion

The Australian warning focuses on a physical product linked to a serious injury, while the recent British decision addresses marketing practices that can create demand before regulatory approval. Together, they show how oversight must cover the full supply chain: advertisements, online sellers, product testing, prescribing and adverse-event reporting. The Australian regulator has also stressed that imported or illegally supplied medicines do not receive the controls applied to products approved for domestic supply.

The immediate question is whether testing or patient reports identify further counterfeit batches or additional injuries. Authorities will also be watching how quickly sellers change names, platforms or packaging after warnings are issued. For consumers and clinicians, the central distinction is not between one fashionable peptide and another, but between medicines supplied through regulated prescribing channels and products whose identity and concentration cannot be trusted.